HB 320 Delaware House · 151st General Assembly (2021-2022)

AN ACT TO AMEND TITLE 24 RELATING TO PRESCRIBING MEDICATIONS FOR THE TERMINATION OF PREGNANCY.

Summary
In 2000, the United States Federal Drug Administration ("FDA") first approved the Risk Evaluation and Mitigation Strategy ("REMS") for Mifeprex; and approved the generic version of Mifeprex, Mifepristone, in 2019. A regimen approved by the FDA in 2016 for Mifeprex and Mifepristone includes the use of Misoprostol. Under the REMS approved by the FDA, healthcare providers who wish to prescribe Mifepristone, Misoprostol, or Mifeprex must complete a Prescriber Agreement before ordering and dispensing the medication. Physicians assistants and advanced practiced registered nurses (APRNs) are healthcare providers who are eligible to prescribe these medications under the REMS. This bill allows physician assistants and advanced practice registered nurses to prescribe medication for the termination of pregnancy including Mifeprex, Mifepristone, and Misoprostol.
Bill status signed all 5 stages cleared
Introduction
Mar 2022
Committee Review
Apr 2022
House Passage
Mar 2022
Senate Passage
Apr 2022
Signed into Law
Apr 2022
Introduced Mar 9, 2022 Signed Apr 28, 2022
Floor votes · House Mar 24, 2022

How they voted

This bill passed the Senate by voice vote (no roll call recorded).
Full legislative history

Actions timeline

Total actions
8
Key actions
5
Committee
2
Apr 28, 2022
Signed into law
Signed by Governor
executive
Apr 7, 2022
Upper · Passed
Passed By Senate. Votes: 14 YES 7 NO
upper
Apr 5, 2022
Upper · Passed
Reported Out of Committee (Legislative Oversight & Sunset) in Senate with 3 Favorable
upper
Mar 31, 2022
Introduced
Re-Assigned to Legislative Oversight & Sunset Committee in Senate
upper
Mar 24, 2022
Introduced
Assigned to Health & Social Services Committee in Senate
upper
Mar 24, 2022
Lower · Passed
Passed By House. Votes: 25 YES 15 NO 1 ABSENT
lower
Mar 16, 2022
Lower · Passed
Reported Out of Committee (Health & Human Development) in House with 5 Favorable, 3 On Its Merits
lower
Mar 9, 2022
Introduced
Introduced and Assigned to Health & Human Development Committee in House
lower
7 primary · 10 co-sponsors

Sponsors